A peer-reviewed validation study found that patients with high OncoPrism-NSCLC scores had a 71% response rate to checkpoint inhibitor-based treatment, compared with 36% in lower-scoring groups. The analysis included 1,487 patients across four datasets, although the prospective clinical utility of using the test to choose treatment remains unproven.
EmeraNova has entered a commercialization collaboration involving Hyalomatrix, an established hyaluronic acid-based wound dressing, to expand access across hospitals, wound clinics and surgical settings. The arrangement adds another tissue restoration technology to its portfolio but does not represent a new FDA clearance or acquisition.
Delve Bio has launched a plasma metagenomic sequencing service designed to identify DNA and RNA pathogens using a database covering more than 68,000 organisms. The test promises results the day after sample receipt, but plasma-specific diagnostic accuracy and clinical utility remain important questions.
Cyted Health's DETECT-ME study reported 90% sensitivity and 86% specificity for Barrett's esophagus across 324 participants at 18 US sites. The capsule sponge test also identified all cases of dysplasia and esophageal adenocarcinoma in the reported analysis, although subgroup sizes and broader screening performance require careful interpretation.
Aptar Pharma has obtained European CE marking for LuerVax and its optional Spray Divider, establishing a medical device compliance framework for intranasal vaccine administration. The milestone builds on clinical development use of the platform but does not constitute approval of any vaccine delivered through it.
Telix will present 20 research abstracts at EANM 2026, including updates on pivotal brain and kidney cancer therapy trials, interim prostate cancer treatment findings and Phase 3 imaging data from China. The congress showcases a broad radiopharmaceutical pipeline, but most investigational programmes have not yet reported registrational efficacy results.
Abram Scientific has received a DARPA contract worth up to $8.3 million to advance CoagCare, a portable blood coagulation testing platform designed to provide results in under 10 minutes. The award supports military and civilian development, but regulatory clearance and clinical performance validation remain outstanding.
Providence Medical Technology has announced FDA clearance for CORUS PCSS 3D-T, a porous titanium posterior cervical fusion implant. Its established platform has randomized clinical evidence, but the new implant's incremental clinical benefit remains to be demonstrated.
Vantis Vascular has received FDA 510(k) clearance for a 6F version of its CrossFAST delivery system, expanding compatibility with intravascular imaging and calcium-modification devices. The November launch builds on encouraging early clinical experience, although comparative evidence remains limited.
CSQ Bio has established a surgical commercialization business and introduced INNESTO Rx, a bovine collagen powder scheduled for US sales in January 2027. The product uses an existing FDA-cleared device platform, but clinical differentiation, reimbursement and distribution economics remain unproven.